Ampio Pharmaceuticals, Inc. (AMPE)
USD 0.0
(-0.0%)
USD 0.0
(-0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.73 Million USD | -57.79% |
| 2022 | 13.58 Million USD | -65.0% |
| 2021 | 38.82 Million USD | 69.7% |
| 2020 | 22.87 Million USD | 63.4% |
| 2019 | 14 Million USD | -0.21% |
| 2018 | 14.03 Million USD | -8.39% |
| 2017 | 15.31 Million USD | 12.64% |
| 2016 | 13.59 Million USD | -73.03% |
| 2015 | 50.41 Million USD | -28.25% |
| 2014 | 70.26 Million USD | 95.09% |
| 2013 | 36.01 Million USD | 39.35% |
| 2012 | 25.84 Million USD | 32.67% |
| 2011 | 19.48 Million USD | 2541.62% |
| 2010 | 737.52 Thousand USD | 2303.85% |
| 2009 | 30.68 Thousand USD | -6.85% |
| 2008 | 32.93 Thousand USD | 3.74% |
| 2007 | 31.74 Thousand USD | 5.29% |
| 2006 | 30.15 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q1 | 10.73 Million USD | -21.0% |
| 2023 Q4 | 5.73 Million USD | -24.98% |
| 2023 Q3 | 7.64 Million USD | -16.43% |
| 2023 Q2 | 9.14 Million USD | -14.77% |
| 2023 FY | 5.73 Million USD | -57.79% |
| 2022 Q4 | 13.58 Million USD | -27.87% |
| 2022 FY | 13.58 Million USD | -65.0% |
| 2022 Q3 | 18.83 Million USD | -30.78% |
| 2022 Q2 | 27.21 Million USD | -16.99% |
| 2022 Q1 | 32.78 Million USD | -15.55% |
| 2021 Q4 | 38.82 Million USD | 72.76% |
| 2021 FY | 38.82 Million USD | 69.7% |
| 2021 Q1 | 21.72 Million USD | -5.04% |
| 2021 Q2 | 26.7 Million USD | 22.94% |
| 2021 Q3 | 22.47 Million USD | -15.86% |
| 2020 Q2 | 11.86 Million USD | 34.07% |
| 2020 Q1 | 8.84 Million USD | -36.81% |
| 2020 Q3 | 15.54 Million USD | 31.05% |
| 2020 Q4 | 22.87 Million USD | 47.18% |
| 2020 FY | 22.87 Million USD | 63.4% |
| 2019 FY | 14 Million USD | -0.21% |
| 2019 Q3 | 15.96 Million USD | -23.58% |
| 2019 Q2 | 20.88 Million USD | 65.88% |
| 2019 Q1 | 12.59 Million USD | -10.24% |
| 2019 Q4 | 14 Million USD | -12.29% |
| 2018 Q4 | 14.03 Million USD | -9.91% |
| 2018 Q1 | 14.66 Million USD | -4.25% |
| 2018 Q2 | 11.67 Million USD | -20.41% |
| 2018 Q3 | 15.57 Million USD | 33.44% |
| 2018 FY | 14.03 Million USD | -8.39% |
| 2017 Q2 | 13.06 Million USD | 20.55% |
| 2017 FY | 15.31 Million USD | 12.64% |
| 2017 Q4 | 15.31 Million USD | 63.15% |
| 2017 Q3 | 9.38 Million USD | -28.16% |
| 2017 Q1 | 10.83 Million USD | -20.28% |
| 2016 Q3 | 16.82 Million USD | 2.81% |
| 2016 Q2 | 16.36 Million USD | -25.12% |
| 2016 Q4 | 13.59 Million USD | -19.19% |
| 2016 FY | 13.59 Million USD | -73.03% |
| 2016 Q1 | 21.85 Million USD | -56.65% |
| 2015 Q2 | 57.92 Million USD | -7.51% |
| 2015 FY | 50.41 Million USD | -28.25% |
| 2015 Q1 | 62.62 Million USD | -10.88% |
| 2015 Q4 | 50.41 Million USD | -11.67% |
| 2015 Q3 | 57.07 Million USD | -1.45% |
| 2014 Q2 | 84.98 Million USD | -8.26% |
| 2014 Q3 | 77.15 Million USD | -9.21% |
| 2014 Q4 | 70.26 Million USD | -8.92% |
| 2014 FY | 70.26 Million USD | 95.09% |
| 2014 Q1 | 92.62 Million USD | 157.17% |
| 2013 Q3 | 40.78 Million USD | 89.91% |
| 2013 Q2 | 21.47 Million USD | -15.82% |
| 2013 Q1 | 25.51 Million USD | -1.29% |
| 2013 FY | 36.01 Million USD | 39.35% |
| 2013 Q4 | 36.01 Million USD | -11.69% |
| 2012 Q2 | 15.15 Million USD | -8.31% |
| 2012 Q4 | 25.84 Million USD | -9.11% |
| 2012 Q3 | 28.43 Million USD | 87.63% |
| 2012 Q1 | 16.53 Million USD | -15.15% |
| 2012 FY | 25.84 Million USD | 32.67% |
| 2011 Q4 | 19.48 Million USD | 28.13% |
| 2011 Q3 | 15.2 Million USD | -8.61% |
| 2011 Q2 | 16.63 Million USD | 31.18% |
| 2011 Q1 | 12.68 Million USD | 1619.69% |
| 2011 FY | 19.48 Million USD | 2541.62% |
| 2010 Q3 | 85.08 Thousand USD | -71.18% |
| 2010 FY | 737.52 Thousand USD | 2303.85% |
| 2010 Q2 | 295.21 Thousand USD | -49.59% |
| 2010 Q1 | 585.6 Thousand USD | 1808.7% |
| 2010 Q4 | 737.52 Thousand USD | 766.86% |
| 2009 Q4 | 30.68 Thousand USD | 1.3% |
| 2009 Q3 | 30.28 Thousand USD | -3.04% |
| 2009 Q2 | 31.23 Thousand USD | -3.95% |
| 2009 FY | 30.68 Thousand USD | -6.85% |
| 2009 Q1 | 32.52 Thousand USD | -1.26% |
| 2008 Q4 | 32.93 Thousand USD | 6.56% |
| 2008 Q2 | 34.82 Thousand USD | 11.46% |
| 2008 Q3 | 30.9 Thousand USD | -11.25% |
| 2008 FY | 32.93 Thousand USD | 3.74% |
| 2008 Q1 | 31.24 Thousand USD | -1.59% |
| 2007 Q4 | 31.74 Thousand USD | -19.61% |
| 2007 Q3 | 39.49 Thousand USD | 0.0% |
| 2007 FY | 31.74 Thousand USD | 5.29% |
| 2006 Q4 | 30.15 Thousand USD | 0.0% |
| 2006 FY | 30.15 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | 70.404% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 94.784% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 92.957% |
| Azitra, Inc. | 5.11 Million USD | -12.13% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | 42.577% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -5850.763% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | 42.749% |
| CEL-SCI Corporation | 30.52 Million USD | 81.211% |
| iBio, Inc. | 28.73 Million USD | 80.038% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 94.322% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | 24.196% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 91.253% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -31.21% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | 36.507% |
| NanoViricides, Inc. | 12.82 Million USD | 55.267% |
| Oragenics, Inc. | 4.96 Million USD | -15.498% |
| BiomX Inc. | 58.15 Million USD | 90.137% |
| BiomX Inc. | 58.15 Million USD | 90.137% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | 93.207% |
| Palatin Technologies, Inc. | 10.74 Million USD | 46.603% |
| Scorpius Holdings, Inc. | 51.03 Million USD | 88.761% |
| Theriva Biologics, Inc. | 60.21 Million USD | 90.474% |